BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 26, 2012
 |  BioCentury  |  Emerging Company Profile

BioMetrx: RASS restoration

BioMetrx developing plant-derived Rasstore to reduce prostate cancer growth

BioMetrx LLC has early data for its Rasstore suggesting that restoring levels of the tumor suppressor gene RASSF1A may lead to superior safety and efficacy compared to current prostate cancer therapies.

Rasstore selectively inhibits an isoform of DNA methyltransferase, which in turn leads to up-regulation of Ras association domain family 1A (RASSF1A). BioMetrx believes up-regulation of RASSF1A prevents tumor growth.

According to co-founder and Chief Scientist Milton Brown, methylation of RASSF1A has been linked to disruptions in cell cycle control and resistance to apoptosis in solid tumors, including prostate, colorectal and lung cancers.

Rasstore also down regulates cyclin D1 (CCND1; BCL1), which is involved in cell cycle progression and may contribute to tumorigenesis. The company believes this mechanism is how Rasstore ultimately kills tumor cells.

Rasstore is a fluorescent carbazole analog of mahanine, a natural product derived from the curry leaf plant Murraya koenigii.

In mouse models of prostate cancer, 10 mg/kg Rasstore reduced tumor volume by about 40%, up-regulated expression of RASSF1A and down-regulated CCND1...

Read the full 842 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >